E.M.H. Schmitz

Determination of dabigatran, rivaroxaban and apixaban by ultra‐performance liquid chromatography – tandem mass spectrometry (UPLC‐MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants

E.M.H. Schmitz, Kjm Kristel Boonen, D.J.A. van den Heuvel et al. · Journal of Thrombosis and Haemostasis · 2014 · 169 citations · Full text

Thrombosis, Therapeutic Drug Monitoring, Therapy Monitoring +13

Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12‐month multicentre observational prospective cohort study

E.M.H. Schmitz, Paul J. Boekema, Jan-Willem Straathof et al. · Alimentary Pharmacology & Therapeutics · 2017 · 70 citations · Full text

Therapeutic drug monitoring of infliximab: performance evaluation of three commercial ELISA kits

E.M.H. Schmitz, Daan van de Kerkhof, Dörte Hamann et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 2015 · 51 citations

Determination of dabigatran and rivaroxaban by ultra-performance liquid chromatography-tandem mass spectrometry and coagulation assays after major orthopaedic surgery

Mark W.M. Schellings, Kjm Kristel Boonen, E.M.H. Schmitz et al. · Thrombosis Research · 2016 · 35 citations

Major Orthopaedic Surgery, Coagulation Assays, Medicine +7

Therapeutic drug monitoring (TDM) as a tool in the switch from infliximab innovator to biosimilar in rheumatic patients: results of a 12-month observational prospective cohort study

E.M.H. Schmitz, S. Benoy - De Keuster, A. J. L. Meier et al. · Clinical Rheumatology · 2017 · 19 citations · Full text

Rheumatoid Disorder, Rheumatology, Therapeutic Drug Monitoring +11